Pfizer COVID-19 Vaccine and PAXLOVID Antiviral Analyst Call 2021

Pfizer held an analyst and investor call on December 17, 2021 to discuss its COVID-19 vaccine developed with BioNTech and PAXLOVID, its investigational oral antiviral candidate. The presentation covers the clinical potential, regulatory status, manufacturing, distribution and revenue expectations for both therapies as part of a comprehensive COVID-19 approach.